Branded drug companies are actively making it harder for generic drug manufacturers to develop and test new generic products, harming consumers and the federal government by keeping drug prices high and reducing competition. This bill would address the problem by making it easier for generic drug companies to get the information and branded product they need for generic development.
It’s incredibly expensive and difficult to develop a new branded drug, and the manufacturers that manage to do so rightfully should be able to make money on their branded product for however long it takes a generic company to develop the same formulation. Since this bill doesn’t end the seven-year exclusivity period for branded products, it’s unlikely to actually help generic products come to market faster — the only likely effect is that it’ll create frivolous lawsuits that don’t benefit anyone.